CDEK
← All organizations

HRA Pharma

For profitContributed to NME

Also known as: HRA Pharma | HRA PHARMA | LAB HRA PHARMA | LABORATOIRE HRA | LABORATORIE HRA

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jan 1, 2004

First marketed drug

Jul 1, 1996

First NDA

Aug 13, 2010

Last known activity

Sep 6, 2019

Acquired by Perrigo on Sep 8, 2021

Timeline

1960s

  1. Dec 4, 1961

    metyrapone— Marketing Organization

1990s

  1. Jul 1, 1996

    HRA Pharma— Founded

2000s

  1. Jan 1, 2005

    Celogos— Acquired

2010s

  1. Aug 13, 2010

    ulipristal— NDA Secondary Org

  2. Aug 13, 2010

    ulipristal— NDA Organization

2020s

  1. Sep 8, 2021

    Perrigo— Acquired By

Drugs by trial phase (5 distinct, 12 trials)

Phase 4 (3 own, 0 via acquisition)

Phase 3 (1 own, 0 via acquisition)

Phase 2 (1 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (4)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (12)

Details

Founded
Paris, FR Jul 1, 1996
First NDA
Aug 13, 2010
Last known activity
Sep 6, 2019

Designations held

  • Priority review

Notes

Acquired by Astorg Partners 19 Feb 2016